Key result
Continuing of ASA during transurethral surgery resulted in no significant differences in postoperative haemorrhage or operative revision compared to discontinuing ASA.
Why the study?
Does continuation of acetylsalicylic acid 100 mg increase bleeding complications in patients undergoing transurethral interventions?
Cohort (n=346)
Does continuation of acetylsalicylic acid 100 mg increase bleeding complications in patients undergoing transurethral interventions?
Answers are grounded in this paper and cite their sources.
Continuation of 100 mg ASA during transurethral interventions increases postoperative bleeding in TURP but does not significantly increase the need for surgical revision, suggesting it is a feasible approach for patients with verified indications for platelet inhibition.
PURPOSE: To determine whether transurethral surgery under platelet inhibition is a feasible procedure. Before transurethral resection of prostate (TURP) or bladder tumours (TURB), the administration of platelet-inhibiting medication is often interrupted due to possible bleeding complications. We studied the performance of TURP and TURB under the current recommendations of the American College of Chest Physicians (ACCP) on perioperative platelet inhibition. MATERIALS AND METHODS: Patients assigned for transurethral intervention were preoperatively divided into the following risk groups: low, medium and high cardio- or cerebrovascular risk. In patients with a low-risk profile, acetylsalicylic acid (ASA) was discontinued. Patients of the medium risk group continued taking 100 mg of ASA. Patients of the high-risk group receiving dual platelet inhibition (ASA + clopidogrel) were not treated operatively. In total 346 patients from the low and medium risk groups underwent transurethral intervention. RESULTS: Forty-two out of 198 TURP were performed under 100 mg of ASA. Without ASA, a significantly shorter length of stay and earlier removal of the transurethral catheter was documented. In the parameters postoperative haemorrhage and operative revision, no significant differences were observed. Thirty-two out of 148 TURB were performed under 100 mg of ASA. Regarding the length of stay, time until catheter removal, postoperative haemorrhage and operative revision, no significant differences were found under ASA. Only significantly longer continuous irrigation was documented under ASA. CONCLUSION: In the case of a verified indication for use of platelet inhibitors, it is possible to avoid discontinuation and the consequent increased risk of thromboembolic incidents in transurethral surgery is admissible.
No takes yet. Share an insight, caveat, or question.
Wenders et al. (2012) conducted a cohort in Transurethral interventions (TURP/TURB) (n=346). Acetylsalicylic acid (ASA) vs. Discontinuation of ASA was evaluated on Postoperative haemorrhage, operative revision, length of stay, and time until catheter removal. Continuing of ASA during transurethral surgery resulted in no significant differences in postoperative haemorrhage or operative revision compared to discontinuing ASA.
Synapse has enriched 10 related papers. Consider them for comparative context: